Transgene

Transgene OCF Margin

The Operating Cash Flow Margin of Transgene (TNG.PA) as of Oct 8, 2026 is -387.24 %. In the previous year, Operating Cash Flow Margin was -454.17 % — a change of -14.74% (higher).

OCF Margin

-387.24 %

YoY

-14.74%

Last updated:

Operating Cash Flow Margin of Transgene is 2024 -387.24 % . Operating Cash Flow Margin of Transgene was 2023 -454.17 % . It decreases by -14.74% higher compared to the previous year.

The Transgene OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2017
-474.32 EUR
Jan 1, 2018
-400.64 EUR
Jan 1, 2019
-168.57 EUR
Jan 1, 2020
-307.63 EUR
Jan 1, 2021
-152.28 EUR
Jan 1, 2022
-202.99 EUR
Jan 1, 2023
-454.17 EUR
Jan 1, 2024
-387.24 EUR
The Transgene OCF Margin history
YEAROCF MarginYoY
-387.24 %-14.74%
-454.17 %+123.74%
-202.99 %+33.30%
-152.28 %-50.50%
-307.63 %+82.50%
-168.57 %-57.92%
-400.64 %-15.53%
-474.32 %+23.27%
-384.80 %-18.48%
-472.05 %-3.40%
-488.66 %—
Access this data via the Eulerpool API

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Operating Cash Flow Margin of Transgene is -387.24 % in 2024.

Operating Cash Flow Margin of Transgene changed from -454.17 % to -387.24 %, representing a -14.74% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Transgene since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Transgene with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Transgene

All Key Metrics — Transgene